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Abstract
Importance—Primary central nervous system (CNS) germ cell tumors (GCT) are a 
heterogeneous group of tumors that are still poorly understood. In North America, GCTs comprise 
approximately 1% of primary brain tumors in pediatric and young adult patients. GCTs can occur 
as pure or mixed subtypes; they are divided into germinomas, which are the most common 
subtype, and non-germinomatous germ cell tumors (NGGCTs), which consist of approximately 
one-third of GCTs and include teratomas, embryonal carcinomas, choriocarcinomas, and yolk sac 
tumors.
Observations—While the etiology of primary CNS GCT is not entirely clear, the various 
subtypes are lineage-related and may involve progenitor germ cells that fail to migrate and become 
trapped in midline locations. Primary CNS GCT most commonly arises in the pineal region but 
also occur in other areas. Presenting symptoms can include headache, Parinaud syndrome, 
diabetes insipidus, precosious puberty, ataxia, or hemiparesis. Diagnosis of primary CNS GCTs 
can be difficult and is often delayed. Various imaging studies and tumor markers can assist in 
specific diagnosis. Treatment plans differ depending on the subtype of GCT and may vary among 
physicians and institutions. Germinomas have a favorable prognosis with a greater than 90% 
overall survival, while NGGCTs only have survival rates ranging from 40–70%.
Conclusions and Relevance—Germinomas seem to be most effectively treated with 
chemotherapy and radiation, while NGGCT usually require surgical resection, chemotherapy, and 
radiation with the exception of mature teratomas frequently curable with surgery alone. Gamma 
knife radiosurgery is a promising treatment that may be an effective additional treatment option. 
Cytogenic and molecular analyses are attempting to further specify the different GCT subtypes 
and are helping to direct the development of distinct therapeutic targets to improve treatment and 
prognosis.
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INTRODUCTION
The second most common location for extragonadal germ cell tumors (GCT) is the central 
nervous system (CNS)1. Primary CNS GCT are a heterogeneous group of tumors that are 
still poorly understood in regards to etiology and molecular biology, which in turn can lead 
to difficulties in diagnosis and treatment. In North America, germ cell tumors (GCTs) 
comprise approximately 1% of primary brain tumors in pediatric and young adult patients 
with a median age of diagnosis of 16 years 2. In the United States, the overall GCT 
incidence is 0.6 per million per year while 1.0 per million per year in Europe and 2.7 per 
million per year in Japan3. Primary CNS GCTs can occur as pure or mixed subtype tumors; 
in the United States and Europe, GCTs are commonly are divided into germinomas, which 
are the most common subtype, and non-germinomatous germ cell tumors (NGGCTs), which 
consist of approximately one-third of GCTs and include teratomas, embryonal carcinomas, 
choriocarcinomas, and yolk sac tumors3–6. Teratomas can be classified further as mature, 
containing entirely fully differentiated tissues, or immature, containing mostly embryonic or 
fetal tissues7. Alternatively Japanese classification of GCT subtypes is separated into good, 
intermediate, and poor prognosis groups8. The good prognosis group includes pure 
germinoma and mature teratoma; the intermediate prognosis group contains mixed tumors 
with mainly germinoma or teratoma and immature teratomas; and the poor prognosis group 
consists of choriocarcinoma, yolk sac tumor, embryonal carcinoma, and mixed tumors with 
components from any of the subtypes of this group 9,10.
CNS GCTs occur more frequently in the Asian population and are present more commonly 
in males with significantly higher rates in the pineal location; however, suprasellar 
germinomas were noted more frequently in females 1,2,4,11. Goodwin and colleagues noted 
that among 700 cases of GCTs across 17 diverse regions, NGGCT specifically are not 
associated with a particular sex, location, race, or age with the exception of infant patients 
(Table 1) 2. Timely diagnosis of primary central nervous system GCTs can be challenging 
due to nonspecific symptoms12,13. Additionally, treatment plans can differ depending on the 
subtype of GCT and can vary among different physicians and institutions. We reviewed the 
current literature to discuss the pathophysiology, clinical presentation, assessment and 
diagnosis, treatment, molecular biology, and prognosis of primary CNS GCTs.
DISCUSSION
Pathophysiology
While the etiology of primary CNS GCT is unclear, and there are several hypotheses that 
attempt to explain this disease process2. Germ cells are believed to be pluripotent and able to 
differentiate into any type of cell14. These cells originate in the yolk sac of the embryo 
around the third to fourth week of gestation, normally destined for the ovaries or testes but 
can aberrantly migrate to other locations for unknown reasons14 Some believe that 
progenitor germ cells wrongly migrate and become trapped in midline locations along the 
anteroposterior axis of the body as supported by extracranial GCTs in other midline sites, 
such as mediastinum and retroperitonium, which share certain characteristics such as DNA 
methylation, gene expression, marker secretion, and chromosomal alterations9,11. Barkova 
and colleagues noted that CNS GCT had similar DNA damage response activation patterns 
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to that of gonadal GCT rather than that of CNS-originating tumors which share a common 
environment15.
Evidence shows that teratomas can arise from other non-progenitor germ cells, suggesting 
that other GCT subtypes may also have this capability of developing from non-germ cell 
lines9. Another theory posits that endogenous neural stem cells in the brain are the likely 
origin of primary CNS GCT since lack of methylation of the SNRPN gene previously 
linking GCT to progenitor germ cells has been found to be more similar in pattern to human 
neural stem cells16. Overexpression of a single particular gene, Oct4, was able to stimulate 
the development of normal progenitor cells in the brain from neural stem cells; the different 
GCT subtypes seem to be “lineage-related” as evidenced by their recurrence as a different 
subtype or mixed subtype following treatment 9,17.
Clinical Presentation
While CNS GCT usually arise in the pineal region, they can also occur in supraseller areas, 
fourth ventricle, basal ganglia, and thalamus; about 5–10% of patients will have tumor 
present in both pineal and supraseller regions, which happens more frequently in patients 
with germinomas 6,18. In bifocal disease, it is unknown whether tumor spread occurred or 
simultaneous tumor development in two different sites took place 6. Phi et al suggested that 
metastatic spread seemed more likely based on high ventricular seeding rates noted in 
patients with bifocal CNS GCTs 13. Intracranial germinomas typically arise between 7 and 
30 years of age, while NGGCT commonly occur from birth to 20 years17. Symptoms of 
primary CNS GCTs may include Parinaud syndrome due to hydrocephalus or compression 
of the tectal plate, ataxia and dysmetria if affecting the superior cerebellar peduncles, 
diabetes insipidus secondary to either hydrocephalus or additional tumor presence in the 
suprasellar area affecting the neurophypophysis, and precocious puberty from hormones 
secreted from certain GCT 6,19. Patients may also experience headache, oculomotor paresis, 
facial paresis, or hemiparesis20,21.
Assessment & Diagnosis
Diagnosis of CNS GCTs is delayed in approximately 54% of patients due to nonspecific 
symptoms that are usually present for greater than 6 months before any diagnostic imaging 
is obtained 5,6,13. GCTs are typically found on computerized tomography (CT) or magnetic 
resonance imaging (MRI) of the brain 19. Additionally, certain tumor markers may be 
detected in the serum or cerebrospinal fluid (CSF) to aid in diagnosis 19. In 2013, 117 
multidisciplinary specialists from 25 countries developed Delphi consensus statements 
regarding the investigation and management of intracranial GCT, which required at least 
70% of votes to support a statement and at least 60% participation of voters. In regards to 
statements biological work-up, they concluded that serum and CSF alpha-fetoprotein (AFP) 
and human chorionic gonadotrophic hormone (HCG) should be measured to aid in 
diagnosis3. Yolk sac tumors can secrete AFP; choriocarcinomas can release HCG6. 
Germinomas have been associated with mild increases in total HCG and may show elevated 
placental alkaline phosphatase (PLAP) 6. Elevated AFP and HCG can sometimes occur with 
immature teratomas22. Pure embryonal carcinomas are not known to secrete any tumor 
markers; however, they tend to occur mixed with other GCT subtypes, especially yolk sac 
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tumors23. Immunohistochemical markers should also be determined3. Germinomas highly 
express c-kit/CD117, OCT3/4, and PLAP. Embryonal carcinomas stain strongly for CD30 
and CK AE1/3. Yolk sac tumors are typically positive for AFP expression, while 
choriocarcinomas tend to express HCG3,24. However, normal tumor markers do not 
definitively rule out the presence of a GCT 25.
CNS GCTs have a tendency to spread through the neuroaxis making extensive metastatic 
evaluation a necessity and should include MRI with gadolinium of the brain and spine 6. 
Positive tumors markers can indicate malignant disease with AFP levels greater than 
1000ng/ml considered high risk and may require intensified chemotherapy and radiation 5,6 
Even with negative or decreasing tumor marker levels, suspected metastatic disease should 
be explored and treated 26. Without a positive tumor marker result, a biopsy is required for 
definitive diagnosis35,6. If tumor markers are detected in the blood or CSF, then a biopsy is 
not necessarily required for diagnosis 3,11,27. However although bifocal intracranial tumors 
with elevated HCG and normal AFP was considered pathonomic for germinomas, Aizer et al 
found that 21% of their patients with bifocal disease and elevated HCG with normal to 
mildly elevated AFP were diagnosed with NGGCT, which is of importance to avoid 
undertreatment28. See Table 2 for a diagnostic summary of primary CNS GCT.
Treatment
The management of primary CNS GCT can vary but typically includes a multimodal 
treatment plan. Chemotherapy alone without radiation has only proven ineffective resulting 
in increased relapse rates and worse outcomes 6,25,29,30. Additionally, diabetes insipidus is a 
risk factor for complications when chemotherapy regimens include cisplatin or ifosfamide 
based protocols31. Survival significantly increases when patients receive radiation therapy4. 
Radiation alone has provided excellent survival for patients but can later result in secondary 
malignancies or neurocognitive and neuroendocrine sequelae, such as decreased processing 
speed, working memory, and visual memory6,25,32.
Germinomas are virtually curable with radiation therapy alone or more recently neoadjuvant 
chemotherapy plus radiation 27,32,33. One study noted the outcomes of 24 patients with CNS 
germinomas treated with lowered radiation doses and a variety of chemotherapy agents, 
including carboplatin, etoposide, ifosfamide; they found that progression free survival at 5 
years was 96% and overall survival was 100% 25. Bouffet and colleagues also found that 
combining local radiation and chemotherapy for the treatment of non-metastatic 
germinomas achieved excellent survival rates34. Cyclophosphamide is another agent under 
investigation for treating GCTs and was noted as a feasible and well-tolerated additional 
treatment option35. In addition, pre-treatment and post-treatment neuropsychological and 
neurocognitive testing did not differ significantly at a mean follow-up of 38 months and then 
189 months 25. More specifically, treatment of germinomas has developed from high dose 
craniospinal irradiation (CSI) to now include platinum-based chemotherapy followed by 
boost radiation to the tumor bed and whole ventricular system3 radiation therapy since most 
germinomas recur within the ventricular system36. Oral etoposide may also be used 
palliatively to treat CNS germinomas after conventional chemotherapy and radiation; 
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response to this treatment has been noted for other refractory or recurrent brain tumors in the 
pediatric population 37.
Only 20–40% of NGGCT are effectively controlled with radiation alone and, therefore, 
require chemotherapy and radiation in addition to complete surgical resection when 
possible27,33,38. Chemotherapy prior to radiation therapy has significantly improved survival 
to 60–70% for patients with NGGCTs 6,39. The most active agents for NGGCT include 
carboplatin, cisplatin, etoposide, gemcitabine, ifosfamide, taxanes, and vinblastine6. 
Masutani et el reports effective protocols using carboplatin or cisplatin with etoposide for 
treating germinomas or intermediated prognosis NGGCTs, but could not control poor 
prognosis NGGCT even with the use of ifosphamide-cisplatin-etoposide8. Surgical resection 
alone has not been shown to be sufficient treatment for NGGCTs with the exception of 
mature teratoma 3,6,20,27. Although similar final outcomes in the United States and Japan, 
surgery is more frequently included in GCT treatment protocol in Japan than in the United 
States1. Yet surgical resection after completion of both chemotherapy and radiation occurs 
more commonly in Japan, while surgery after chemotherapy but followed by radiation 
typically occurs in the US and Europe3. Immature teratomas typically respond poorly to a 
cisplatin chemotherapy regimen but, for better outcomes, still require a combination of 
chemotherapy and radiation along with surgical resection when feasible22.
In the United States, CSI and boost radiation to tumor bed is typically used to treat 
NGGCT27,28; while Japanese protocols prefer the use of radiation at the tumor site and focal 
surrounding area for intermediate prognosis NGGCTs but recommends CSI for poor 
prognosis NGGCTs8,10. The European standard is to treat non-metastatic NGGCT with only 
local radiation therapy40. One study found that CSI was associated with significantly 
increased overall survival for poor prognosis NGGCT, suggesting the use of greater than 36 
Gy for CSI and 54 Gy or greater radiation to the primary tumor site41. Additionally, Khafaga 
and colleagues reported that tumor radiation doses greater than 50Gy is preferred for 
improving outcomes41,42. Several studies have found increased survival with resection of 
residual tumor after chemotherapy and radiation, suggesting that surgery plays an important 
role in treating NGGCT particularly with failed radiologic response after initial 
chemotherapy and radiation36,43. Kochi et al treated 11 patients with NGGCT with 
chemotherapy and whole brain/ventricular radiation with boost radiation to tumor bed 
followed by complete excision of any residual tumor; this regimen resulted in a 91% 5-year 
overall survival43. Yet, Jinguji and colleagues found that an initial treatment strategy 
including gross total resection either before or after whole-brain radiation and chemotherapy 
provided effective therapeutic outcomes38. According to the Delphi consensus, treatment of 
NGGCT should include chemotherapy and radiation with CSI specially used in metastatic 
disease and resection of residual tumor3.
Endoscopic third ventriculostomy (ETV) should be considered since it is has been show to 
provide superior safety, diagnostic efficacy, and decreased morbidity and mortality at 
treating hydrocephalus and obtaining biopsies of tumors compared with open surgery or 
external ventricular drainage 9,19. The Delphi consensus agreed that ETV is favored over 
other surgical interventions when feasible for the treatment of obstructive hydrocephalus3. 
ETV is ideal for non-emergent situations when intracranial blood pressure is well controlled; 
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however, risks to consider include lesion to the fornix and insufficient tissue sample for 
diagnosis of the tumor, especially for mixed GCT not diagnosed through elevated hormone 
markers9,19. The benefit of open surgical resection is still debated. While some report no 
significant differences in survival among any subtypes regardless of extent of surgical 
resection, others concluded that improved survival occurred for patients specifically with 
NGGCTs and advised radical removal over biopsy or subtotal resection 4,6. However, 
germinomas are almost never treated with surgical resection unless residual tumor is 
persistent after other therapies are utilized 27.
Gamma knife radiosurgery (GKRS) is another intervention under investigation and may 
provide benefit in the treatment for GCTs. Although no prospective study has taken place, 
one retrospective study found the average pineal tumor size decreased by roughly half 6 
months after treatment with complete tumor disappearance in 39% of patients after 1 year44. 
Survival rates for GCTs specifically were 62.4% at 3 years and 54.4% at 5 years with local 
tumor control rates of 88% at 3 years and 77.27% at 5 years 44. Huang et al observed that 
patients with NGGCT treated with GKRS experienced increased 5-year survival22. GKRS 
should be investigated further but appears to be relatively effective as an additional treatment 
option. See Table 3 for a treatment summary of primary CNS GCT.
A stem cell treatment is another area of research being explored for treating primary CNS 
GCT. The idea of using high dose chemotherapy with autologous stem cell rescue (ASCR) is 
meant to eliminate or at least reduce the radiation dose administers to young children with 
brain tumors to decrease the risk of long term adverse effects45. Tada and colleagues treated 
6 patients with NGGCT with ASCR after chemotherapy, radiation therapy, and surgical 
excision. All patients survived one to seven years after diagnosis and lived with good 
performance status; however, mild liver dysfunction occurred in all patients along with 
hearing disturbance in half of patients46. The Delphi consensus agreed that relapsed 
malignant NGGCT should be treated with high dose chemotherapy followed by 
hematopoietic stem cell rescue along with surgery and radiation when possible3. 
Additionally, one case report mentioned the use of dendritic cell-based immunotherapy in 
which a 22-year old male with a germinoma was given five inoculations, resulting in rapid 
tumor shrinkage and decreased serum bHCG levels47.
Molecular Biology and Possible Therapeutic Targets
Cytogenic and molecular analyses of pineal tumors have been increasingly pursued for 
further specification of the different GCT subtypes6. However, this scientific pursuit may be 
difficult as Schneider et al failed to observe any differences in the genetic profiles of 
germinomas and NGGCT in 19 patient samples, but the number of chromosomal imbalances 
was greater in the NGGCT samples48. One case report mentioned a patient who had a 
germinoma at age 5 but developed a yolk sac tumor 14 years later; it was unclear if or how 
the tumors were related but could not be distinctly separated since there was location overlap 
of the tumors 37. Chromosomal analysis found that germinomas and mature teratomas 
revealed a mean number of 12.8 chromosomal changes (8 gains and 4.8 deletions)5. CNS 
GCT were also noted to have frequent aberrations of CCND2 (12p13), RB1 (13q14), and 
PRDM14 (8q13) genes, which play a role in the cyclin/CDK-RB-E2F pathway involved in 
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transcriptional regulation of primordial germ cell specification and development of CNS 
GCT9,49. Chromosome 4 and 5 losses were reported more commonly in primary CNS GCT 
than compared to extracranial GCT50. Interestingly, many pineal region GCT were found to 
have multiple copies of the X chromosomes, which may explain the high incidence of GCT 
in patients with Klinefelter’s syndrome50. Additionally, Schulte and colleagues found global 
DNA demethylation in 49 germinoma samples compared to other tumors and normal 
tissues51.
Furthermore, decreased sensitivity to radiation therapy and chemotherapy along with poor 
prognosis were noted in 20% of CNS GCT that expressed p21 and 94% of CNS GCT that 
expressed p539. Somatic alterations in the AKT/mTOR pathway have been noted in 
intracranial GCT; CNS GCT have also been linked to point mutations of the proto-oncogene 
KIT, especially among germinomas, which are associated with chromosomal 
instability6,9,51,52. One study found mutations in the KIT/RAS signaling pathway in over 
50% of GCT patients, involving KIT, KRAS, NRAS and CBL, along with alterations in the 
AKT/mTOR pathway in 19% of GCT patients52. There are at least eight tyrosine kinase 
inhibitors targeting KIT that have been approved, which could potentially benefit patients 
with CNS GCT hopefully reducing or eliminating the use of radiation and/or chemotherapy; 
additionally, the therapeutic agent Selumetinib has shown great efficacy in preclinical trials 
targeting KRAS-mutated non-small cell lung cancer cells52. The use of Dasatinib has been 
suggested for patients with CNS GCT as it has been an effective tyrosine kinase inhibitor 
against myeloid leukemia cell lines with CBL mutations; however, one study investigating 
Dasatinib as a treatment for GCT was unclear of the benefits considering the multimodal 
treatment plans of the patients52,53.
Prognosis
One study of 373 patients with pineal GCT reported having a 5-year overall survival of 80%, 
which carried the best survival rates compared to the other pineal tumor types4. Worse 
prognosis was significantly associated with female sex, age greater than 18 years, NGGCT, 
and lack of radiation therapy in treatment4. Prognosis is relatively favorable for germinomas 
showing a greater than 90% 5-year survival and overall survival even with metastasis 
compared to NGGCT with survival rates ranging from 30–70%6,25,36. Yet one study of 14 
patients with NGGCT found that neoadjuvant combined chemotherapy and radiation therapy 
followed by complete resection of residual tumor resulted in a 5-year survival of 93%54. 
After analyzing 153 CNS GCT cases, Matsutani et al determined 10- and 20-year survival 
rates patients with pure germinomas as 93% and 81%, 10-year survival rates patients with 
mature teratomas and immature teratomas as 93% and 71 respectively, and 3-year survival 
rate of embryonal carcinoma, yolk sac tumor, and choriocarcinoma as 27%10. Another study 
evaluating the long-term outcomes of 455 germinomas and 94 NGGCT reported an 84.1% 
and 61.9% 20- and 30-year survival rates, respectively, for germinomas, and an 86.7% 
survival rate for both 20- and 30-year time points for NGGCTs55.
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CONCLUSIONS AND FUTURE DIRECTIONS
Primary CNS GCTs are rare and heterogeneous group of malignancies, primarily affecting 
pediatric population and young adults. The most effective treatment for germinomas seems 
to be radiation therapy with neoadjuvant chemotherapy9. On the other hand, NGGCT appear 
to be best treated with chemotherapy and radiation followed by gross total resection; 
complete tumor resection alone is the ideal treatment specifically for mature teratomas 
(Table 4) 6,9. Cytogenic and molecular analyses are attempting to further specify the 
different GCT subtypes and are helping to direct the development of distinct therapeutic 
targets to improve treatment and prognosis (Table 4) 9.
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Table 1
Major epidemiologic facts about primary CNS GCT
Germinomas Non-germinomatous germ cell tumors
Males Not associated with a particular sex, location, race, or age with the exception of infant patients
Pineal location
Asian
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Table 3
Main treatments available for primary CNS GCT
Germ Cell Tumors (GCT) Treatment Options
Germinomas Chemotherapy, radiation therapy, GKRS
Non-germinomatous GCT
teratomas
mature Surgical resection
immature Chemotherapy, radiation therapy, surgical resection, GKRS, hematopoietic stem cell rescue
embryonal carcinomas
choriocarcinomas
yolk sac tumors
GKRS= Gamma knife radiosurgery
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Table 4
Current treatment recommendations for primary CNS GCT
Germ Cell Tumors (GCT) Recommendations
Germinomas • 4 cycles of platinum based chemotherapy, usually including etoposide, ifosfamide, 
and either carboplatin or cisplatin8,36,56
• followed by whole ventricular radiotherapy (20-24Gy) and boost radiation (12-16) to 
tumor bed57,58
• if CSF metastasis detected, then craniospinal irradiation also administered36,59,60
Non-germinomatous GCT
teratomas
mature • complete surgical resection6,22,27
immature • 4–6 cycles of neoadjuvant chemotherapy, usually including carboplatin/cisplatin, 
etoposide, and ifosfamide, but may include gemcitabine, taxanes, or vinblastine6,27,56; 
however, immature teratomas do not respond well to cisplatin22
• more intensive chemotherapy regimens are recommended for worse prognosis 
NGGCT10
• craniospinal irradiation (≥36Gy) and boost radiation (≥54Gy) to tumor bed27,28,41 or 
whole brain/ventricular radiation (24-40Gy) with boost radiation (15-30Gy) to tumor 
bed43
• complete surgical resection when possible3,6,28
• Some suggest best protocol for poor prognosis NGGCT should include simultaneous 
radiation and chemotherapy followed by resection of remaining tumor3,8
embryonal carcinomas
choriocarcinomas
yolk sac tumors
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